Efficacy of Postexposure Prophylaxis After Intravaginal Exposure of Pig-tailed Macaques to a Human-derived Retrovirus (human Immunodeficiency Virus Type 2)

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2000 Sep 23

PMID 11000253

Citations 53

Authors

R A Otten

D K Smith

D R Adams

J K Pullium

E Jackson

C N Kim

H Jaffe

R Janssen

S Butera

T M Folks

Affiliations

Soon will be listed here.

Abstract

Postexposure prophylaxis (PEP) after intravaginal exposure to human immunodeficiency virus (HIV) was investigated using the HIV type 2 (HIV-2)/pig-tailed macaque transmission model. PEP for 28 days with the reverse transcriptase inhibitor (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA; tenofovir) was initiated 12 to 72 h following HIV-2 exposure. Systemic infection was not evident in the 12- and 36-h groups, as defined by plasma viremia, cell-associated provirus, antibody responses, and lymph node virus. Breakthrough infection in the 72-h group was detected at week 16 post-virus exposure. These results demonstrate for the first time using a vaginal transmission model that early intervention after high-risk sexual exposures may prevent infection.

Citing Articles

Readiness for HIV Postexposure Prophylaxis (PEP) Decision Making Following Sexual Violence.

Draughon Moret J, Wilson M, Humphrey-Staub J, Porter T, Wellington J, Anderson J Issues Ment Health Nurs. 2024; 45(9):937-947.

PMID: 39173124 PMC: 11792872. DOI: 10.1080/01612840.2024.2366324.

Missed Opportunities: A Narrative Review on Why Nonoccupational Postexposure Prophylaxis for HIV Is Underutilized.

Allan-Blitz L, Mayer K Open Forum Infect Dis. 2024; 11(8):ofae332.

PMID: 39086468 PMC: 11289484. DOI: 10.1093/ofid/ofae332.

Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions.

Mayer K, Allan-Blitz L Lancet HIV. 2023; 10(12):e816-e824.

PMID: 37952551 PMC: 11331403. DOI: 10.1016/S2352-3018(23)00238-2.

Patient and Provider Decision Making About HIV Postexposure Prophylaxis Following Sexual Violence: A Qualitative Analysis.

Anderson J, Boakye M, Draughon Moret J J Assoc Nurses AIDS Care. 2023; 34(6):566-581.

PMID: 37787738 PMC: 10592041. DOI: 10.1097/JNC.0000000000000430.

Concordance of emergency department physicians' decisions on HIV post-exposure prophylaxis with national guidelines: results from a retrospective cohort study.

Heck J, Honer Zu Siederdissen C, Krause O, Schroder S, Schulze Westhoff M, Strunz P Int Health. 2023; 16(2):219-226.

PMID: 37624102 PMC: 10911529. DOI: 10.1093/inthealth/ihad076.

References

Nkengasong J, Kestens L, Ghys P, Koblavi-Deme S, Otten R, Bile C . Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses. 2000; 16(14):1371-8. DOI: 10.1089/08892220050140919. View

Otten R, Ellenberger D, Adams D, Fridlund C, Jackson E, Pieniazek D . Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. J Infect Dis. 1999; 180(3):673-84. DOI: 10.1086/314968. View

Otten R, Brown B, Simon M, Lupo L, Parekh B, Lairmore M . Differential replication and pathogenic effects of HIV-1 and HIV-2 in Macaca nemestrina. AIDS. 1994; 8(3):297-306. DOI: 10.1097/00002030-199403000-00002. View

Miller C, Marthas M, Torten J, Alexander N, Moore J, Doncel G . Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J Virol. 1994; 68(10):6391-400. PMC: 237059. DOI: 10.1128/JVI.68.10.6391-6400.1994. View

Lohman B, McChesney M, Miller C, McGowan E, Joye S, Van Rompay K . A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol. 1994; 68(11):7021-9. PMC: 237139. DOI: 10.1128/JVI.68.11.7021-7029.1994. View

Tsai C, Follis K, Sabo A, Beck T, Grant R, Bischofberger N . Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995; 270(5239):1197-9. DOI: 10.1126/science.270.5239.1197. View

. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 1995; 44(50):929-33. View

Trivedi P, Horejsh D, Hinds S, Hinds PW I, Wu M, Salvato M . Intrarectal transmission of simian immunodeficiency virus in rhesus macaques: selective amplification and host responses to transient or persistent viremia. J Virol. 1996; 70(10):6876-83. PMC: 190736. DOI: 10.1128/JVI.70.10.6876-6883.1996. View

Mertens T, Belsey E, Stoneburner R, Beer D, Sato P, Burton A . Global estimates and epidemiology of HIV-1 infections and AIDS: further heterogeneity in spread and impact. AIDS. 1995; 9 Suppl A:S259-72. View

10.

Mastro T, de Vincenzi I . Probabilities of sexual HIV-1 transmission. AIDS. 1996; 10 Suppl A:S75-82. DOI: 10.1097/00002030-199601001-00011. View

11.

Bottiger D, Johansson N, Samuelsson B, Zhang H, Putkonen P, Vrang L . Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS. 1997; 11(2):157-62. DOI: 10.1097/00002030-199702000-00004. View

12.

Ridzon R, Gallagher K, Ciesielski C, Ginsberg M, Robertson B, Luo C . Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med. 1997; 336(13):919-22. DOI: 10.1056/NEJM199703273361304. View

13.

Katz M, Gerberding J . Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med. 1997; 336(15):1097-100. DOI: 10.1056/NEJM199704103361512. View

14.

Cardo D, Culver D, Ciesielski C, Srivastava P, Marcus R, Abiteboul D . A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997; 337(21):1485-90. DOI: 10.1056/NEJM199711203372101. View

15.

Looney D, McClure J, Kent S, Radaelli A, Kraus G, Schmidt A . A minimally replicative HIV-2 live-virus vaccine protects M. nemestrina from disease after HIV-2(287) challenge. Virology. 1998; 242(1):150-60. DOI: 10.1006/viro.1997.8992. View

16.

Miller C . Host and viral factors influencing heterosexual HIV transmission. Rev Reprod. 1998; 3(1):42-51. DOI: 10.1530/ror.0.0030042. View

17.

Miller C, Marthas M, Greenier J, Lu D, Dailey P, Lu Y . In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. J Virol. 1998; 72(4):3248-58. PMC: 109796. DOI: 10.1128/JVI.72.4.3248-3258.1998. View

18.

Tsai C, Emau P, Follis K, Beck T, Benveniste R, Bischofberger N . Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998; 72(5):4265-73. PMC: 109656. DOI: 10.1128/JVI.72.5.4265-4273.1998. View

19.

Pauza C, Horejsh D, Wallace M . Mucosal transmission of virulent and avirulent lentiviruses in macaques. AIDS Res Hum Retroviruses. 1998; 14 Suppl 1:S83-7. View

20.

. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998; 47(RR-7):1-33. View